First-line anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy in Japanese mucosal melanoma: A retrospective, multicenter study (JMAC study)

被引：0

作者：

Nakamura, Y. ^{[1
]}

Namikawa, K. ^{[2
]}

Yoshikawa, S. ^{[3
]}

Kiniwa, Y. ^{[4
]}

Maekawa, T. ^{[5
]}

Yamasaki, O. ^{[6
]}

Isei, T. ^{[7
]}

Matsushita, S. ^{[8
]}

Nomura, M. ^{[9
]}

Nakai, Y. ^{[10
]}

Fukushima, S. ^{[11
]}

Saito, S. ^{[12
]}

Takenouchi, T. ^{[13
]}

Tanaka, R. ^{[14
]}

Kato, H. ^{[15
]}

Otsuka, A. ^{[16
]}

Matsuya, T. ^{[17
]}

Baba, N. ^{[18
]}

Nagase, K. ^{[19
]}

Inozume, T. ^{[20
]}

机构：

[1] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, Saitama, Japan

[2] Natl Canc Ctr Hosp Tsukiji Campus, Dept Dermatol Oncol, Tokyo, Japan

[3] Shizuoka Canc Ctr, Dept Dermatol, Shizuoka, Japan

[4] Shinshu Univ, Dept Dermatol, Matsumoto, Nagano, Japan

[5] Jichi Med Univ Hosp, Dept Dermatol, Shimotsuke, Tochigi, Japan

[6] Okayama Univ, Dept Dermatol, Okayama, Japan

[7] Osaka Int Canc Inst, Dept Dermatol Oncol, Osaka, Japan

[8] Natl Hosp Org, Kagoshima Med Ctr, Dept Dermatooncol Dermatol, Kagoshima, Japan

[9] Kyoto Univ, Grad Sch Med, Dept Therapeut Oncol, Kyoto, Japan

[10] Mie Univ, Dept Dermatol, Tsu, Mie, Japan

[11] Kumamoto Univ, Dept Dermatol, Kumamoto, Japan

[12] Gunma Univ, Dept Dermatol, Maebashi, Gumma, Japan

[13] Niigata Canc Ctr Hosp, Dept Dermatol, Niigata, Japan

[14] Kawasaki Med Sch, Dept Dermatol, Kurashiki, Okayama, Japan

[15] Nagoya City Univ, Dept Dermatol, Nagoya, Aichi, Japan

[16] Kyoto Univ Hosp, Dept Dermatol, Kyoto, Japan

[17] Asahikawa Med Univ, Dept Dermatol, Asahikawa, Hokkaido, Japan

[18] Univ Fukui, Dept Dermatol, Fukui, Japan

[19] Saga Univ, Dept Dermatol, Saga, Japan

[20] Chiba Univ, Dept Dermatol, Chiba, Japan

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1431

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1046P

引用

页码：S876 / S876

页数：1

共 50 条

[1] Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)
Nakamura, Y.
Namikawa, K.
Yoshikawa, S.
Kiniwa, Y.
Maekawa, T.
Yamasaki, O.
Isei, T.
Matsushita, S.
Nomura, M.
Nakai, Y.
Fukushima, S.
Saito, S.
Takenouchi, T.
Tanaka, R.
Kato, H.
Otsuka, A.
Matsuya, T.
Baba, N.
Nagase, K.
Inozume, T.
Fujimoto, N.
Kuwatsuka, Y.
Onishi, M.
Kaneko, T.
Onuma, T.
Umeda, Y.
Ogata, D.
Takahashi, A.
Otsuka, M.
Teramoto, Y.
Yamazaki, N.
[J]. ESMO OPEN, 2021, 6 (06)
[2] Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients
Nakamura, Yasuhiro
Namikawa, Kenjiro
Kiniwa, Yukiko
Kato, Hiroshi
Yamasaki, Osamu
Yoshikawa, Shusuke
Maekawa, Takeo
Matsushita, Shigeto
Takenouchi, Tatsuya
Inozume, Takashi
Nakai, Yasuo
Fukushima, Satoshi
Saito, Shintaro
Otsuka, Atsushi
Fujimoto, Noriki
Isei, Taiki
Baba, Natsuki
Matsuya, Taisuke
Tanaka, Ryo
Kaneko, Takahide
Onishi, Masazumi
Kuwatsuka, Yutaka
Nagase, Kotaro
Onuma, Takehiro
Nomura, Motoo
Umeda, Yoshiyasu
Yamazaki, Naoya
[J]. EUROPEAN JOURNAL OF CANCER, 2022, 176 : 78 - 87
[3] Comparing the clinical efficacies of anti-PD-1 antibody monotherapy and anti-PD-1 and anti-CTLA-4 combination therapy as first-line immunotherapy in Japanese advanced acral melanoma: A retrospective, multicenter study (JAMP-neo study).
Nakamura, Yasuhiro
Kiniwa, Yukiko
Kato, Hiroshi
Yamasaki, Osamu
Maekawa, Takeo
Matsushita, Shigeto
Takenouchi, Tatsuya
Inozume, Takashi
Nakai, Yasuo
Fukushima, Satoshi
Saito, Shintaro
Otsuka, Atsushi
Fujimoto, Noriki
Isei, Taiki
Baba, Natsuki
Matsuya, Taisuke
Tanaka, Ryo
Kaneko, Takahide
Onishi, Masazumi
Yoshikawa, Shusuke
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[4] Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study
Umeda, Yoshiyasu
Yoshikawa, Shusuke
Kiniwa, Yukiko
Maekawa, Takeo
Yamasaki, Osamu
Isei, Taiki
Matsushita, Shigeto
Nomura, Motoo
Nakai, Yasuo
Fukushima, Satoshi
Saito, Shintaro
Takenouchi, Tatsuya
Tanaka, Ryo
Kato, Hiroshi
Otsuka, Atsushi
Matsuya, Taisuke
Baba, Natsuki
Nagase, Kotaro
Inozume, Takashi
Onuma, Takehiro
Kuwatsuka, Yutaka
Fujimoto, Noriki
Kaneko, Takahide
Onishi, Masazumi
Namikawa, Kenjiro
Yamazaki, Naoya
Nakamura, Yasuhiro
[J]. EUROPEAN JOURNAL OF CANCER, 2021, 157 : 361 - 372
[5] Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies
Robert, Caroline
Mateus, Christina
[J]. BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2014, 198 (02): : 297 - 308
[6] PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma
Ellebaek, Eva
Khan, Shawez
Bastholt, Lars
Schmidt, Henrik
Haslund, Charlotte Aaquist
Donia, Marco
Svane, Inge Marie
[J]. EUROPEAN JOURNAL OF CANCER, 2024, 198
[7] Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
Gide, Tuba N.
Quek, Camelia
Menzies, Alexander M.
Tasker, Annie T.
Shang, Ping
Holst, Jeff
Madore, Jason
Lim, Su Yin
Velickovic, Rebecca
Wongchenko, Matthew
Yan, Yibing
Lo, Serigne
Carlino, Matteo S.
Guminski, Alexander
Saw, Robyn P. M.
Pang, Angel
McGuire, Helen M.
Palendira, Umaimainthan
Thompson, John F.
Rizos, Helen
da Silva, Ines Pires
Batten, Marcel
Scolyer, Richard A.
Long, Georgina V.
Wilmott, James S.
[J]. CANCER CELL, 2019, 35 (02) : 238 - +
[8] Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma
Reddy, Swathi B.
Possick, Jennifer D.
Kluger, Harriet M.
Galan, Anjela
Han, Dale
[J]. JOURNAL OF IMMUNOTHERAPY, 2017, 40 (08) : 307 - 311
[9] Combination immunotherapy using anti-PD-1/PD-L1 plus anti-CTLA-4 antibodies
Reck, Martin
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S249 - S249
[10] Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center
Afzal, Muhammad Z.
Shirai, Keisuke
[J]. MELANOMA RESEARCH, 2018, 28 (04) : 341 - 347

← 1 2 3 4 5 →